Abstract: The present disclosure aims to provide a method of efficiently manufacturing a cell mass, a cell structure, or a three-dimensional tissue body using a culturing surface coated with a temperature-responsive polymer or a temperature-responsive polymer composition. The manufacturing method of a cell mass, a cell structure, or a three-dimensional tissue body of the present disclosure includes seeding and culturing cells on a culturing surface coated with a temperature-responsive polymer or a temperature-responsive polymer composition.

Abstract: Provided is a drug superior for preventing and/or treating dementia. It contains a carbostyril derivative of the following formula (1) (wherein R is a cycloalkyl group, A is a lower alkyl group, and a single bond or a double bond is present between the 3-position and the 4-position of the carbostyril nucleus) and dihydroquercetin.

Abstract: A myocardial excitation determining apparatus which can support the determination of excitation dynamics of the myocardium during atrial fibrillation is provided. A myocardial excitation determining apparatus has: an acquiring section 2 which acquires an intracardiac electrocardiogram of a subject; a processing section 3 which computes to produce visualized data indicating a state of excitation in the myocardium, based on the intracardiac electrocardiogram; and a determining section 4 which determines the type of excitation dynamics of the myocardium based on the visualized data.

Abstract: Provided is a cerebral blood flow measurement method of quantitatively measuring cerebral blood flow, the measurement method including: a tracer introducing step of introducing a tracer into a blood vessel; a light applying step of applying measurement light including an absorption wavelength of the tracer to a head; a light detecting step of detecting the measurement light propagating in the head and generating a detection signal based on light intensity of the measurement light; and a calculation step of calculating cerebral blood flow on the basis of a relative change over time ?Q of a concentration of the tracer in a brain tissue which is acquired on the basis of the detection signal and a predetermined relationship between a change over time of a concentration Pa of the tracer in an artery of the head and cerebral blood flow.

Abstract: The purpose of the present invention is to provide a novel medical application of pluripotent stem cells (muse cells) in regeneration medicine. The present invention provides a cell preparation and a pharmaceutical composition which are for amelioration and treatment of brain disorders resulting from fetal growth retardation, such as abnormal motor quality or abnormal neurological development, and which contain SSEA-3 positive pluripotent stem cells isolated from a mesenchymal tissue from a live body or cultured mesenchymal cells. It is assumed that this cell preparation is based on a mechanism where muse cells that are administered to objects having the disorders are engrafted on an impaired brain tissue, thereby ameliorating or treating the disorders.

Abstract: Provided is a method for predicting probability of ischemic stroke onset. A method for predicting a risk of ischemic stroke onset, the method comprising: a detection step of detecting presence or absence of a RNF213 p.R4810K gene variant in a sample derived from a test subject who does not develop ischemic stroke; and a determination step of determining whether a probability of ischemic stroke onset of the test subject is high or not, based on the presence or absence of the RNF213 p.R4810K gene variant in the detection step, and gender information of the test subject. A genetic marker for predicting a risk of ischemic stroke onset using gender information, comprising a RNF213 p.R4810K gene variant. A biomarker for predicting a risk of ischemic stroke onset using gender information, comprising a polypeptide encoded by a RNF213 p.R4810K gene variant.

Abstract: A myocardial excitation complementation/visualization apparatus includes an acquiring section that acquires intracardiac electrocardiograms of a subject, the intracardiac electrocardiograms being recorded by a recording unit having a plurality of electrodes, a processing section that performs a computation for completing and visualizing a state of excitation in a myocardium of the subject based on the intracardiac electrocardiograms, and a displaying section that displays the state of excitation in the myocardium of the subject based on an output of the processing section. The processing section includes a first generating section, a correcting section, a second generating section, and a third generating section. The displaying section displays a change of the state of excitation in the myocardium of the subject based on the visualized data.

Abstract: To provide a peptide that selectively activates type 2 neuromedin U receptor and is chemically stable under physiological conditions. A peptide represented by Formula (1) described in the specification.

Abstract: Provided is a use for a peptide in surface-treating a medical device or medical material to be used in contact with blood, with which it is possible to obtain a medical device or medical material that can achieve highly efficient vascular endothelialization through the use of a peptide uniquely binding to vascular endothelial cells. Also provided are: a peptide suitable for use in said surface treatment; a method for producing a medical device or medical material surfaced-treated with said peptide and to be used in contact with blood; and a surface treatment agent including said peptide, said agent to be used in surface-treating a medical device or medical material to be used in contact with blood. In the present invention, a medical device or medical material is surface-treated using a peptide that includes any one of ten specific amino acid sequences and uniquely binds to the surface of endothelial progenitor cells.

Abstract: An object of the present invention is to provide a method for producing a mesenchymal stromal cell composition, comprising conveniently and aseptically separating high-purity amnion-derived MSCs by performing enzyme treatment only once. According to the present invention, the following are provided: a method for producing a mesenchymal stromal cell composition, comprising: performing enzyme treatment of an amnion with collagenase and thermolysin and/or dispase; and filtering the enzyme-treated amnion through a mesh; a method for producing a cryopreserved mesenchymal stromal cell composition; and a therapeutic agent comprising as an active ingredient the mesenchymal stromal cell composition for a disease selected from graft-versus-host disease, inflammatory bowel disease, systemic lupus erythematosus, liver cirrhosis, or radiation enteritis.

Abstract: The present invention provides a connective tissue body formation substrate which can form a film connective tissue having a desired thickness and both surfaces in a desired surface condition without prolonging the time required for formation of the connective tissue. Specifically, two tissue formation surfaces 2a and 2b are faced with each other with a tissue formation space 3 being interposed therebetween. A slit 9 is formed in the tissue formation surface 2b so that the tissue formation space 3 communicates with an outside of the substrate. A connective tissue body formation substrate 1 is installed in an environment where a biological tissue material is present. A connective tissue intrudes into the tissue formation space 3 from the slit 9. Both surfaces of the film connective tissue are formed so as to match the substrate surface.

Abstract: An object of the present invention is to provide a method for producing a mesenchymal stromal cell composition, comprising conveniently and aseptically separating high-purity amnion-derived MSCs by performing enzyme treatment only once. According to the present invention, the following are provided: a method for producing a mesenchymal stromal cell composition, comprising: performing enzyme treatment of an amnion with collagenase and thermolysin and/or dispase; and filtering the enzyme-treated amnion through a mesh; a method for producing a cryopreserved mesenchymal stromal cell composition; and a therapeutic agent comprising as an active ingredient the mesenchymal stromal cell composition for a disease selected from graft-versus-host disease, inflammatory bowel disease, systemic lupus erythematosus, liver cirrhosis, or radiation enteritis.

Abstract: An object of the present invention is to provide a method for producing a mesenchymal stromal cell composition, comprising conveniently and aseptically separating high-purity amnion-derived MSCs by performing enzyme treatment only once. According to the present invention, the following are provided: a method for producing a mesenchymal stromal cell composition, comprising: performing enzyme treatment of an amnion with collagenase and thermolysin and/or dispase; and filtering the enzyme-treated amnion through a mesh; a method for producing a cryopreserved mesenchymal stromal cell composition; and a therapeutic agent comprising as an active ingredient the mesenchymal stromal cell composition for a disease selected from graft-versus-host disease, inflammatory bowel disease, systemic lupus erythematosus, liver cirrhosis, or radiation enteritis.

Abstract: A peptide that enables surface treatment of a scaffold for tissue repair that makes it possible to accelerate the repair of living tissue without using a material that negatively affects the repair of living tissue, a complex containing this peptide, a scaffold for tissue repair surface treated using this peptide or this complex, a surface treatment method for a scaffold for tissue repair using this peptide or this complex, and a treatment solution or set of treatment solutions to be used in this surface treatment method. Surface treatment of a scaffold for tissue repair is conducted by combining glycosaminoglycan and a peptide containing adhesive sites and basic sites each comprising predetermined amino acid residues.

Abstract: The present invention provides a method for forming a connective tissue body, which enables extending the ranges of design values in terms of shape, dimension, etc., of the connective tissue body. This method comprises: a fat treatment step for removing fat contained in a connective tissue body, which is formed in an environment where a biological tissue material is present, from the interior of the connective tissue body while the connective tissue body is being set in a molding tool, and for causing the shape of the connective tissue body to follow the shape of the molding tool; and a bioinert solution treatment step for immersing the connective tissue body, together with the molding tool, in a bioinert solution while the connective tissue body is being shaped so as to follow the shape of the molding tool after the fat treatment step.

Abstract: Provided is a drug superior for preventing and/or treating dementia. It contains a carbostyril derivative of the following formula (1) (wherein R is a cycloalkyl group, A is a lower alkyl group, and a single bond or a double bond is present between the 3-position and the 4-position of the carbostyril nucleus) and dihydroquercetin.

Abstract: A tissue body formation device for forming a connective tissue body in an environment where a living tissue material is present is provided with: an inner member having a tissue body formation surface that serves as a surface for forming a connective tissue body; and a covering member which is provided with a covering surface that constitutes an external surface of the tissue body formation device, and that covers a part of the tissue body formation surface. The covering member further has a plurality of connection parts that connect the outer side of the tissue body formation device to the tissue body formation surface. Each of the connection parts has an opening in the covering surface. Each of the openings has a minimum dimension of at least 0.5 mm in a direction along the covering surface. The openings account for 20-40% per unit area of the covering surface.

Abstract: A myocardial excitation determining apparatus which can support the determination of excitation dynamics of the myocardium during atrial fibrillation is provided. A myocardial excitation determining apparatus has: an acquiring section 2 which acquires an intracardiac electrocardiogram of a subject; a processing section 3 which computes to produce visualized data indicating a state of excitation in the myocardium, based on the intracardiac electrocardiogram; and a determining section 4 which determines the type of excitation dynamics of the myocardium based on the visualized data.

Abstract: The present disclosure aims to provide a method of efficiently manufacturing a cell mass, a cell structure, or a three-dimensional tissue body using a culturing surface coated with a temperature-responsive polymer or a temperature-responsive polymer composition. The manufacturing method of a cell mass, a cell structure, or a three-dimensional tissue body of the present disclosure includes seeding and culturing cells on a culturing surface coated with a temperature-responsive polymer or a temperature-responsive polymer composition.

Abstract: The object of the present invention is to provide a method for producing a cell population comprising mesenchymal stem cells having a high specific growth rate which are useful for promptly producing large amounts of cell formulations. The present invention provides a method for producing a cell population comprising mesenchymal stem cells, comprising: a step of treating a cell population comprising mesenchymal stem cells having different proliferative ability by physical stimulation or chemical stimulation, so as to select mesenchymal stem cells having relatively high proliferative ability, wherein the selected mesenchymal stem cells having relatively high proliferative ability are negative for CD106, and the expression level of a metallothionein family gene is increased in comparison to the expression level thereof in the cell population before the treatment by the physical stimulation or chemical stimulation.